Last updated Jun 6, 2026
Pfizer
Evidence Sources
7
Competitive Findings
0
Portfolio Developments
2
Regulatory Precedents
8
Clinical Programs
2
Confidence Coverage
73%
Audit
- Competitor findings: 0
- Portfolio developments: 2
- Self-competition findings removed: 2
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Supportive Care
- Diabetes
- SGLT2 Inhibitor
Highest priority development: Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor Competition
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 73%
Active Signals
2
Investigate Priority
0
Opportunity Score
58
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 30FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma
Diabetes · SGLT2 Inhibitor
- MonitorJun 7, 2026Score 28FDA Grants AP Status for MESNA ANDA203364 Submission by RISING
Oncology · Supportive Care
Related Assets
Portfolio asset pages with evidence-based assessments.
- Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor CompetitionModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera - Regulatory Developments Reshape Competitive Landscape in Oncology Supportive CareModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)PfizerFDAPortfolio
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferenceLow Confidence · 0%
FDA approval
Sources (3)PfizerFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — DAPAGLIFLOZIN (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — DAPAGLIFLOZIN (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — DAPAGLIFLOZIN (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor CompetitionModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov - Regulatory Developments Reshape Competitive Landscape in Oncology Supportive CareModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Pfizer right now?
- Which regulatory precedents should Pfizer monitor in Oncology and Supportive Care?
- How does Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor Competition compare to the nearest competitive programs?
- What signals require immediate investigation for Pfizer?
- Summarize the strategic implications of recent developments for Pfizer.
- Where is the greatest uncertainty in Pfizer's competitive positioning?